机构:[1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[2]Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[3]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, The People’s Republic of China[4]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, The People’s Republic of China[5]Ninth School of Clinical Medicine, Peking University, Beijing 100038, The People’s Republic of China[6]Department of Intensive Care Unit, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[7]Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[8]Department of General Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, The People’s Republic of China外科科室普通外科昆明医科大学附属第一医院[9]Yunnan University, Kunming 650091, Yunnan, The People’s Republic of China[10]Department of General Surgery, The Affiliated Hospital of Yunnan University, Kunming 650091, Yunnan, The People’s Republic of China
Colon cancer is one of the most common cancers in digestive system, and its prognosis remains unsat-isfactory. Therefore, this study aimed to identify gene signatures that could effectively predict the prognosis of colon cancer patients by examining the data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database. LASSO-Cox regression analysis generated a five-gene signature (DCBLD2, RAB11FIP1, CTLA4, HOXC6 and KRT6A) that was associated with patient survival in the TCGA cohort. The prognostic value of this gene signature was further validated in two independent GEO datasets. GO enrichment revealed that the function of this gene signature was mainly associated with extracellular matrix organization, collagen-containing extracellular matrix, and extracellular matrix structural constituent. Moreover, a nomogram was established to facilitate the clini-cal application of this signature. The relationships among the gene signature, mutational landscape and immune infiltration cells were also investigated. Importantly, this gene signature also reliably predicted the overall survival in IMvigor210 anti-PD-L1 cohort. In addition to the bioinformatics study, we also conducted a series of in vitro ex-periments to demonstrate the effect of the signature genes on the proliferation, migration, and invasion of colon cancer cells. Collectively, our data demonstrated that this five-gene signature might serve as a promising prognostic biomarker and shed light on the development of personalized treatment in colon cancer patients.
基金:
National Natural Science Foundation of China [81900499, 81860100, 82060525]; National Key Research and Development Projects [2017YFC1309200, YLXL20170002]; Yunnan province science and Technology Hall Youth Academic and tech- nical leader Reserve Talents Project [202005AC160057]; Reserve talents of high- level health technical talents in Yunnan Pro- vince; Yunnan Province ?; high level talent training support plan?; training plan -special program for young top talent [YNWR-QNBJ-2019-243]; Yunnan high level talent training support plan -? [RLMY20- 200019]
第一作者机构:[1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[2]Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[3]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, The People’s Republic of China[4]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, The People’s Republic of China[5]Ninth School of Clinical Medicine, Peking University, Beijing 100038, The People’s Republic of China
通讯作者:
通讯机构:[1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[2]Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, The People’s Republic of China[3]Beijing International Science and Technology Cooperation Base for Cancer Metabolism and Nutrition, Beijing 100038, The People’s Republic of China[4]Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, The People’s Republic of China[5]Ninth School of Clinical Medicine, Peking University, Beijing 100038, The People’s Republic of China[10]Department of General Surgery, The Affiliated Hospital of Yunnan University, Kunming 650091, Yunnan, The People’s Republic of China[*1]Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10th Tieyi Road, Haidian District, Beijing 100038, The People’s Republic of China.[*2]Department of General Surgery, The Affiliated Hospital of Yunnan University, No. 176 Qingnian Road, Wuhua District, Kunming 650091, Yunnan, The People’s Republic of China.
推荐引用方式(GB/T 7714):
Qiankun Zhu,Benqiang Rao,Yongbing Chen,et al.Original In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer[J].AMERICAN JOURNAL OF CANCER RESEARCH.2023,13(1):45-+.
APA:
Qiankun Zhu,Benqiang Rao,Yongbing Chen,Pingping Jia,Xin Wang...&Hanping Shi.(2023).Original In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer.AMERICAN JOURNAL OF CANCER RESEARCH,13,(1)
MLA:
Qiankun Zhu,et al."Original In silico development and in vitro validation of a novel five-gene signature for prognostic prediction in colon cancer".AMERICAN JOURNAL OF CANCER RESEARCH 13..1(2023):45-+